Currently, anti-CD19 CAR-T cell therapies for B-cell malignancies are the most advanced engineered T cell therapies being tested. Clinical trials in ALL and CLL have exhibited robust and striking clinical efficacy.

References of how our cellular receptors function.

CTLA-4, short for Cytotoxic T-Lymphocyte-Associated protein 4 and also called CD152. The first immunecheckpoint receptor to be clinically targeted, is expressed exclusively on T cells where it primarily regulates the amplitude of the early stages.

The basic CAR structure consists of an extracellular antigen-recognition domain attached to an extracellular spacer domain, a trans-membrane region that anchors the receptor in the plasma, and a signaling endodomain.

As a leading technology provider, Creative Biolabs has established CellRapeutics™ Chimeric Antigen Receptor (CAR) Technology platform. Our elite scientists have broad experience in CAR construction, which can supply the best service for you.

Our novel Chimeric Antigen Receptor (CAR) technology platform consists of several key services including CAR construction, pseudoviral particles production and stable transduction.

To augment the antitumor efficacy of 1st-generation CARs, the 2nd-generation CARs were designed to combine the intracellular signaling domains from various costimulatory protein receptors.